Get the Daily Brief
Latest Biotech News
Regulatory safety signal for Vykat XR in Prader-Willi syndrome
A group of physicians and Prader-Willi syndrome experts notified clinicians about potential safety concerns tied to Neurocrine Biosciences’ newly approved Vykat XR (sparсaple?) through the FDA’s...
FDA approvals expand biotech product launches across immunology and oncology
July FDA approvals delivered first products for three biotechs, including Vera Therapeutics’ accelerated approval for Trutakna (atacicept) in primary immunoglobulin A nephropathy, with Celcuity...
FDA rejects radiopharma competitor due to manufacturing issues
The FDA rejected ITM Isotope Technologies Munich’s radiotherapeutic ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors, citing manufacturing problems at a third-party...
Phase 2 success lifts Abcellera’s hot-flashes program
AbCellera reported positive Phase 2 top-line results for ABCL-635, an injectable neurokinin-3 receptor antagonist for menopausal vasomotor symptoms. In a randomized, double-blind,...
Phase 2 failure douses Sionna’s cystic fibrosis add-on strategy
Sionna Therapeutics said its Phase 2 add-on approach for cystic fibrosis did not deliver benefit when combined with Vertex’s Trikafta. In the trial, SION-719 plus Trikafta failed to show a...
Biotech fundraising and VC expansion in the UK
UK biotech investment surged in Q2 2026 to a five-year high, reaching £2.11 billion ($2.84 billion) in equity financing, including a record-breaking £2.05 billion in VCl, according to an interview...
Major rare-disease financing to advance HEREDITARY hemorrhagic telangiectasia (HHT)
Vaderis Therapeutics secured an oversubscribed $152 million Series B to advance engasertib (VAD-044) in hereditary hemorrhagic telangiectasia. The financing was co-led by Life Sciences at Goldman...
New biotech deals for IL-22 and IL-13 in atopic dermatitis via Infinimmune’s Series A
Infinimmune announced a $75 million Series A to advance two antibody programs into the clinic for atopic dermatitis. The round was co-led by Regeneron Ventures and Playground Global, with...
Corporate leadership shift at K2 Therapeutics after Legend exit
Ying Huang, formerly CEO of Legend Biotech, stepped into the CEO role at K2 Therapeutics as part of a C-suite overhaul. K2’s focus includes building a multimodal oncology pipeline and pursuing new...
FDA authorization for a Stargardt-related and oncology-adjacent move in genomics diagnostics (MRD expansion context)
Natera said it is preparing to expand beyond its U.S. MRD footprint after accruing multiple regulatory wins across geographies. The company highlighted FDA approval for Signatera in...
Immunology delivery and anticancer immunity via microbiome-derived signals
Sungkyunkwan University and the University of Michigan reported an oral microbiome nanomedicine designed to boost anticancer immunity, using a small molecule produced by gut bacteria to prime the...
Regulatory and reimbursement: 340B payment and rebate model shifts
HHS’s 340B program rules moved again as CMS and HRSA advanced complementary changes aimed at reshaping how covered entities are paid and how manufacturers supply ceiling-price rebates. CMS...
Late-stage pipeline setbacks and capital preservation after clinical failures
Sionna Therapeutics disclosed that its cystic fibrosis add-on strategy failed in a Phase 2 trial, after the company tested the NBD1 stabilizer SION-719 in combination with Vertex’s Trikafta. The...
Clinical expansion in rare disease: Series B funding for Vaderis hereditary hemorrhagic telangiectasia (HHT)
Vaderis Therapeutics raised an oversubscribed $152 million Series B to push engasertib (VAD-044) into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing was co-led by Life...
FDA approvals: first-of-its-kind therapies and precision diagnostics
The FDA approved Takeda’s Orzeyful (oveporexton), described as the first therapy designed to address the underlying cause of narcolepsy type 1 in adults. The approval follows clearance from...
Immunotherapy durability in inflammatory disease: AbCellera hot-flash Phase 2 and downstream Phase 3 benchmark-setting
AbCellera reported positive top-line Phase 2 results for ABCL635, an investigational NK3R antagonist antibody being developed for moderate-to-severe vasomotor symptoms (hot flashes) due to...
Biologics financing and clinical entry for eczema competitors to Dupixent
Infinimmune secured $75 million in Series A funding to develop antibody candidates for atopic dermatitis, targeting IL-22 with IFX-101 and IL-13 with IFX-201. The financing was positioned as fuel...
Platform funding: Remedium Bio launches durable protein therapeutics Series A
Remedium Bio announced the initial closing of a planned $10 million Series A as it advances its durable protein therapeutics platform toward first-in-human studies. The funding is earmarked for...
Oncology immunotherapy resistance biology: myeloid networks and tumor immune failure
A study in Science Bulletin reported how macrophages contribute to resistance to immune checkpoint blockade in gastric cancer, identifying immune checkpoint therapy as effective only for subsets...
Disease mechanism and translational acceleration: FDA-enabled gene editing trial risk watch and cell therapy pipeline moves
Ribox Therapeutics obtained FDA IND clearance for RXIM-002, a circular RNA (circRNA)-based in vivo CAR-T approach delivered by a targeted lipid nanoparticle. The company will initiate a Phase I...